Induction of human allergen-specific immune regulation following treatment with a combination of Toll-Like Receptor 7 agonist with allergen: an in vit

变应性鼻炎和哮喘是由于th2型对常见吸入过敏原的异常免疫反应所致。现有的治疗方法减轻症状，但不提供疾病进展的改变。与过敏原免疫耐受的发展和潜在疾病病理生理改变相关的唯一治疗方式是过敏原特异性免疫治疗。然而，过敏原免疫疗法有一些局限性，包括需要几年的定期给药，这限制了其有效性和广泛应用。为了提高其疗效和给药方案与免疫增强剂能够以可控的方式促进，已经提出了Th1和/或调节性T细胞和B细胞反应的产生。

Allergic rhinitis and asthma result from aberrant Th2-type immune reactivity against common inhaled allergens. Existing therapies alleviate symptomatology, but do not offer alteration of disease progress. The only therapeutic modality that has been associated with the development of immune tolerance to allergens and modification of underlying disease pathophysiology is allergen specific immunotherapy. However, allergen immunotherapy has several limitations, including the need of regular administration for several years, that restrict its effectiveness and broad application. To improve its efficacy and dosing regimen co-administration with immunopotentiators capable of promoting in a controlled fashion, the generation of Th1 and/or regulatory T and B cell responses has been proposed.